Tumor-associated antigen presentation via major histocompatibility complex class I and II pathway

Tumor-associated antigen presentation via major histocompatibility complex class I and II pathways refers to the biological processes by which peptides derived from proteins within tumor cells are processed and displayed on their surface using specialized glycoproteins called major histocompatibility complex molecules. **MHC class I** molecules present peptides from intracellular proteins—such as mutated oncogenic proteins—to cytotoxic CD8+ T lymphocytes. This is crucial for direct killing of malignant cells by the adaptive immune system. **MHC class II** molecules present peptides derived from extracellular sources—such as phagocytosed debris from dying tumor cells—to CD4+ helper T lymphocytes; these help coordinate broader anti-tumor immunity.[2][4][7] In many cancers, defects in these pathways—including loss or downregulation of key components like HLA genes—allow tumors to evade detection by the immune system.[1] Restoration or enhancement of effective antigen processing/presentation is a central goal in modern cancer immunotherapy strategies.[5] This entry describes an essential *immune process*, not a discrete molecular target such as a receptor, enzyme, transporter, etc.; therefore it should not be considered a canonical therapeutic target itself but rather an important context for understanding how actual targets function within anti-tumor immunity. --- **Note:** The provided name refers broadly to an *immune mechanism*, not a specific molecule/receptor/protein. For structured databases focused on drug targets at the molecular level, this entry would be flagged as "incorrect" because it does not correspond to an individual gene product but rather describes two related cellular processes involving multiple gene products.[6]

Other names

MHC class I and II antigen presentationTumor antigen presentation via MHCAntigen processing and presentation in cancer

Drugs affecting this pathway generally work by enhancing immune recognition of tumor antigens through one or more mechanisms such as: - Upregulation of MHC molecule expression to increase tumor visibility to T cells - Blocking inhibitory signals that suppress T cell activation after antigen recognition